Based on the expert knowledge developed through its specific solutions to fight each individual patient’s cancer (OncoDEEP®, OncoSTRAT&GO®, OncoSELECT® and OncoTRACE), OncoDNA also helps biopharma drug development processes, delivering technology solutions, knowledge about cancer based on integrated information and patient sourcing.
One of the current collaborations we have with a large pharma company consists of identifying patients with specific eligibility criteria (e.g. NSCLC patients with EGFR resistance, or patients showing a lack of response to immunotherapy). We use our platform OncoSHARE to browse recently tested patients and mobilize our sales representatives and distributors to initiate the search for patients of interest. Once a patient has been identified and has agreed to participate in the research project, his/her biopsy sample is used to perform the analyses defined by the project. These consist of our OncoSTRAT&GO solution and extra analyses like IHC and/or other tests performed by the pharma partner.
On 26 June 2017, the European Organisation for Research and Treatment of Cancer (EORTC) under the leadership of Prof. Jean-Pascal Machiels and Dr. Rachel Galot from the EORTC Head & Neck Cancer Group, initiated the first international, multi-centric study utilizing a personalized biomarker-based treatment strategy and immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (H&N).
OncoDNA is one of the major partners in this study, together with the “Institut Roi Albert II” of the Cliniques universitaires Saint-Luc, the “Institut de Recherche Expérimentale et Clinique” (IREC) of the University of Louvain and the EORTC.
This collaboration led to the development of the first international, European-based umbrella biomarker-driven clinical trial for patients suffering from recurrent / metastatic H&N cancer, EORTC 1559 HNCG:UPSTREAM study (NCT03088059).
OncoKDM, transforming cancer data into knowledge driven medicine
OncoKDM is the first personalized bioinformatic assistant that can be customized to your specific needs and your bioinformatics pipeline. It is a highly-secured platform, accessible through the web which will turn your data into useful knowledge, without investment in hardware or IT staff.
OncoKDM can integrate sequencing data from any platform with any other test performed in the laboratory. Through proprietary algorithms, OncoKDM can analyze and integrate the information to enable relevant biological and clinical interpretation. A detailed interactive report is prepared for the oncologist to guide him/her in their choice of the best therapy otpions for the patient.
“Given the expertise of OncoDNA delivering solutions in precision medicine, we initiate this collaboration with enthusiasm to produce a specific SOLTI OncoKDM solution which will integrates the current and future molecular data types that might reveal unappreciated vulnerabilities in the tumor of AGATA patients that will allow us to tailor much better their treatment options”
Sonia Pernas – Medical Oncology Department- Institut Català d’Oncologia